Skip to Content
  1. Authors
  2. Kelsey Tsai

Kelsey Tsai

Kelsey Tsai is an equity analyst for Morningstar Research Services LLC, a wholly owned subsidiary of Morningstar, Inc. She covers biotechnology companies. Before assuming her current role in 2016, Tsai was an associate equity analyst, supporting Morningstar’s coverage of the healthcare sector. She joined Morningstar in 2013 as a data analyst and specialized in exchange-traded funds and variable annuities.

Tsai holds a bachelor’s degree in economics from Georgetown University. She also holds the Chartered Financial Analyst® designation.


Though we've lowered our fair-value estimate of the drugmaker after it announced that it has stopped development of a key drug, we still believe in the potential of Alnylam’s remaining pipeline.